Info

🌱 來自：index

pembro

In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population.

Backlink

• recent
• recent (與 Hsieh-TingdeMac-mini.local 衝突的複本 2024-06-28)
• Stage III-of-Preoperative Chemotherapy for Operable Breast Cancer
• KEYNOTE-181
• Monoclonal Antibodies
• adjuvant therapy of rcc
• Stage II-of-Preoperative Chemotherapy for Operable Breast Cancer
• Polymorphisms
• Pembrolizumab
• Adeno or Other in Stage IV NSCLC Treatment
• PD-L1